Article
Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.
British journal of cancer - 1 Jul 2024
Zwart Koen, van Nassau Sietske C M W, van der Baan Frederieke H, Koopman Miriam, Snaebjornsson Petur, van Gestel Anna J, Vink Geraldine R, Roodhart Jeanine M L
Abstract excerpt
BACKGROUND: Encorafenib-cetuximab has been approved for pretreated BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients based on efficacy demonstrated in the randomized phase III BEACON trial. The aim of this real-world effectiveness study is to improve knowledge on the generalizability of trial results. METHODS: This population-based real-world study includes all mCRC patients in the Netherlands...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.